{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:47:32Z","timestamp":1789829252356,"version":"4.0.1"},"reference-count":50,"publisher":"University of Tokushima Faculty of Medicine","issue":"3.4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Med. Invest."],"published-print":{"date-parts":[[2025]]},"DOI":"10.2152\/jmi.72.298","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:07:22Z","timestamp":1762207642000},"page":"298-307","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of the anti-fibrotic potential of a JAK inhibitor in a bleomycin-induced pulmonary fibrosis model"],"prefix":"10.2152","volume":"72","author":[{"given":"Haruka","family":"Nishimura","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine & Rheumatology, Graduate School of Biomedical Sciences"},{"name":"Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo\u2011ku, Kobe, Hyogo, 650-0017, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kawano","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine & Rheumatology, Graduate School of Biomedical Sciences"},{"name":"Department of Community Medicine for Rheumatology, Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seidai","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine & Rheumatology, Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Imakura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine & Rheumatology, Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine & Rheumatology, Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojin","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine & Rheumatology, Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Haji","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine & Rheumatology, Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Bando","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine & Rheumatology, Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhito","family":"Naito","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine & Rheumatology, Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Kagawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine & Rheumatology, Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Isomura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine & Rheumatology, Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine & Rheumatology, Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Graduate School of Biomedical Sciences, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo\u2011ku, Kobe, Hyogo, 650-0017, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Nishioka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine & Rheumatology, Graduate School of Biomedical Sciences"},{"name":"Department of Community Medicine for Rheumatology, Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"925","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Klemperer P, Pollack AD, Baehr G:Landmark article May 23, 1942:diffuse collagen disease. Acute disseminated lupus erythematosus and diffuse scleroderma. By Paul Klemperer, Abou D. Pollack and George Baehr. J Am Med Assoc 251:1593-1594, 1984","DOI":"10.1001\/jama.1984.03340360059032"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon J, Murphy J, Cohen M, Raghu G, Brown KK:Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 183:372-378, 2011","DOI":"10.1164\/rccm.201004-0622OC"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Castelino FV, Dellaripa PF:Recent progress in systemic sclerosis-interstitial lung disease. Curr Opin Rheumatol 30:570-575, 2018","DOI":"10.1097\/BOR.0000000000000544"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Johnson C, Pinal-Fernandez I, Parikh R, Paik J, Albayda J, Mammen AL, Christopher-Stine L, Danoff S:Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease. Lung 194:733-737, 2016","DOI":"10.1007\/s00408-016-9896-x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Rangel-Moreno J, Hartson L, Navarro C, Gaxiola M, Selman M, Randall TD:Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest 116:3183-3194, 2006","DOI":"10.1172\/JCI28756"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Takeshita M, Suzuki K, Nakazawa M, Kamata H, Ishii M, Oyamada Y, Oshima H, Takeuchi T:Antigen-driven autoantibody production in lungs of interstitial lung disease with autoimmune disease. J Autoimmun 121:102261, 2021","DOI":"10.1016\/j.jaut.2021.102661"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Du Bois RM:An earlier and more confident diagnosis of idiopathic pulmonary fibrosis. Eur Respir Rev 21:141-146, 2012","DOI":"10.1183\/09059180.00000812"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Wijsenbeek M, Cottin V:Spectrum of Fibrotic Lung Diseases. N Engl J Med 383:958-968, 2020","DOI":"10.1056\/NEJMra2005230"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, Frankel SK, Hobbs SB, Huie TJ, Ketzer J, Mannina A, Olson AL, Russell G, Tsuchiya Y, Yunt ZX, Zelarney PT, Brown KK, Swigris JJ:Predictors of mortality in rheumatoid arthritis associated interstitial lung disease. Eur Respir J 47:588-596, 2016","DOI":"10.1183\/13993003.00357-2015"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR;INPULSIS Trial Investigators:Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:2071-2082, 2014","DOI":"10.1056\/NEJMoa1402584"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM;CAPACITY Study Group:Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY):two randomized trials. Lancet 377:1760-1769, 2011","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK;INBUILD Trial Investigators:Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 381:1718-1727, 2019","DOI":"10.1056\/NEJMoa1908681"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Collins BF, Raghu G:Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis. Eur Respir Rev 28:190022, 2019","DOI":"10.1183\/16000617.0022-2019"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Aono Y, Nishioka Y, Inayama M, Ugai M, Kishi J, Uehara H, Izumi K, Sone S:Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 171:1279-1285, 2005","DOI":"10.1164\/rccm.200404-531OC"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Inayama M, Nishioka Y, Azuma M, Muto S, Aono Y, Makino H, Tani K, Uehara H, Izumi K, Itai A, Sone S:A novel IkappaB kinase-beta inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 173:1016-1022, 2006","DOI":"10.1164\/rccm.200506-947OC"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kinoshita K, Aono Y, Azuma M, Kishi J, Takezaki A, Kishi M, Makino H, Okazaki H, Uehara H, Izumi K, Sone S, Nishioka Y:Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 49:536-543, 2013","DOI":"10.1165\/rcmb.2012-0277OC"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Aono Y, Kishi M, Yokota Y, Azuma M, Kinoshita K, Takezaki A, Sato S, Kawano H, Kishi J, Goto H, Uehara H, Izumi K, Nishioka Y:Role of platelet-derived growth factor\/platelet-derived growth factor receptor axis in the trafficking of circulating fibrocytes in pulmonary fibrosis. Am J Respir Cell Mol Biol 51:793-801, 2014","DOI":"10.1165\/rcmb.2013-0455OC"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Sato S, Shinohara S, Hayashi S, Morizumi S, Abe S, Okazaki H, Chen Y, Goto H, Aono Y, Ogawa H, Koyama K, Nishimura H, Kawano H, Toyoda Y, Uehara H, Nishioka Y:Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity. Respir Res 18:172, 2017","DOI":"10.1186\/s12931-017-0654-2"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Koyama K, Goto H, Morizumi S, Kagawa K, Nishimura H, Sato S, Kawano H, Toyoda Y, Ogawa H, Homma S, Nishioka Y:The Tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Lung Fibrosis in Mice. Am J Respir Cell Mol Biol 60:478-487, 2019","DOI":"10.1165\/rcmb.2018-0098OC"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Morizumi S, Sato S, Koyama K, Okazaki H, Chen Y, Goto H, Kagawa K, Ogawa H, Nishimura H, Kawano H, Toyoda Y, Uehara H, Nishioka Y:Blockade of Pan-Fibroblast Growth Factor Receptors Mediates Bidirectional Effects in Lung Fibrosis. Am J Respir Cell Mol Biol 63:317-326, 2020","DOI":"10.1165\/rcmb.2019-0090OC"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. O\u2019Shea JJ, Holland SM, Staudt LM:JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 368:161-170, 2013","DOI":"10.1056\/NEJMra1202117"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Tanaka Y, Luo Y, O\u2019Shea JJ, Nakayamada S:Janus kinase-targeting therapies in rheumatology:a mechanisms-based approach. Nat Rev Rheumatol 18:133-145, 2022","DOI":"10.1038\/s41584-021-00726-8"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Pedroza M, Le TT, Lewis K, Karmouty-Quintana H, To S, George AT, Blackburn MR, Tweardy DJ, Agarwal SK:STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation. FASEB J 30:129-140, 2016","DOI":"10.1096\/fj.15-273953"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Pedroza M, Le TT, Lewis K, Karmouty-Quintana H, To S, George AT, Blackburn MR, Tweardy DJ, Agarwal SK:PDGF-BB induces PRMT1 expression through ERK1\/2 dependent STAT1 activation and regulates remodeling in primary human lung fibroblasts. Cell Signal 28:307-315, 2016","DOI":"10.1016\/j.cellsig.2016.01.004"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Zhou G, Xu Y, He B, Ma R, Wang Y, Chang Y, Xie Y, Wu L, Huang J, Xiao Z:Ionizing radiation modulates vascular endothelial growth factor expression through STAT3 signaling pathway in rat neonatal primary astrocyte cultures. Brain Behav 10:e01529, 2020","DOI":"10.1002\/brb3.1529"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Passalacqua G, Mincarini M, Colombo D, Troisi G, Ferrari M, Bagnasco D, Balbi F, Riccio A, Canonica GW:IL-13 and idiopathic pulmonary fibrosis:Possible links and new therapeutic strategies. Pulm Pharmacol Ther 45:95-100, 2017","DOI":"10.1016\/j.pupt.2017.05.007"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Milara J, Hernandez G, Ballester B, Morell A, Roger I, Montero P, Escriv\u00e1 J, Lloris JM, Molina-Molina M, Morcillo E, Cortijo J:The JAK2 pathway is activated in idiopathic pulmonary fibrosis. Respir Res 19:19-24, 2018","DOI":"10.1186\/s12931-018-0728-9"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Chakraborty D, \u0160umov\u00e1 B, Mallano T, Chen CW, Distler A, Bergmann C, Ludolph I, Horch RE, Gelse K, Ramming A, Distler O, Schett G, \u0160enolt L, Distler JHW:Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nat Commun 8:1130, 2017","DOI":"10.1038\/s41467-017-01236-6"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Choy EH:Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology 58:953-962, 2019","DOI":"10.1093\/rheumatology\/key339"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Dowty ME, Jesson MI, Ghosh S, Lee J, Meyer DM, Krishnaswami S, Kishore N:Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis. J Pharmacol Exp Ther 348:165-173, 2014","DOI":"10.1124\/jpet.113.209304"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Aung WW, Wang C, Xibei J, Horii M, Mizumaki K, Kano M, Okamura A, Kobayashi T, Matsushita T:Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma. J Dermatol Sci 101:174-184, 2021","DOI":"10.1016\/j.jdermsci.2020.12.007"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF, Wen X, Shi J, McGee R, Haley PJ, Shepard S, Rodgers JD, Yeleswaram S, Hollis G, Newton RC, Metcalf B, Friedman SM, Vaddi K:Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis:preclinical characterization of INCB028050. J. Immunol 184:5298-5307, 2010","DOI":"10.4049\/jimmunol.0902819"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Latta VD, Cecchettini A, Del Ry S, Morales MA:Bleomycin in the setting of lung fibrosis induction:From biological mechanisms to counteractions. Pharmacol Res 97:122-130, 2015","DOI":"10.1016\/j.phrs.2015.04.012"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Oh K, Park HB, Byoun OJ, Shin DM, Jeong EM, Kim YW, Kim YS, Melino G, Kim IG, Lee DS:Epithelial transglutaminase 2 is needed for T cell interleukin-17 production and subsequent pulmonary inflammation and fibrosis in bleomycin-treated mice. J Exp Med 208:1707-1719, 2011","DOI":"10.1084\/jem.20101457"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Ashcroft T, Simpson JM, Timbrell V:Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 41:467-470, 1988","DOI":"10.1136\/jcp.41.4.467"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Zhang Y, Dees C, Beyer C, Lin NY, Distler A, Zerr P, Palumbo K, Susok L, Kreuter A, Distler O, Schett G, Distler JH:Inhibition of casein kinase II reduces TGF\u03b2 induced fibroblast activation and ameliorates experimental fibrosis. Ann. Rheum. Dis 74:936-943, 2014","DOI":"10.1136\/annrheumdis-2013-204256"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Tsukui T, Sun KH, Wetter JB, Wilson-Kanamori JR, Hazelwood LA, Henderson NC, Adams TS, Schupp JC, Poli SD, Rosas IO, Kaminski N, Matthay MA, Wolters PJ, Sheppard D:Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis. Nat Commun 11:1920, 2020","DOI":"10.1038\/s41467-020-15647-5"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Ma X, Chen R, Liu X, Xie J, Si K, Duan L:Effects of Matrine on JAK-STAT Signaling Transduction Pathways in Bleomycin Induced Pulmonary Fibrosis. Afr. J. Tradit. Complement. Altern. Med 10:442-448, 2013","DOI":"10.4314\/ajtcam.v10i3.10"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Milara J, Ballester B, Morell A, Ortiz JL, Escriv\u00e1 J, Fern\u00e1ndez E, Perez-Vizcaino F, Cogolludo A, Pastor E, Artigues E, Morcillo E, Cortijo J:JAK2 mediates lung fibrosis, pulmonary vascular remodeling and hypertension in idiopathic pulmonary fibrosis:An experimental study. Thorax 73:519-529, 2018","DOI":"10.1136\/thoraxjnl-2017-210728"},{"key":"40","unstructured":"40. Shi K, Jiang J, Ma T, Xie J, Duan L, Chen R, Song P, Yu Z, Liu C, Zhu Q, Zheng J:Dexamethasone attenuates bleomycin-induced lung fibrosis in mice through TGF-\u03b2, Smad3 and JAK-STAT pathway. Int. J. Clin. Exp. Med 7:2645-2650, 2014"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Bagnato G and Harari S:Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev 24:102-114, 2015","DOI":"10.1183\/09059180.00003214"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Hu X, li, J, Fu M, Zhao X, Wang W:The JAK\/STAT signaling pathway:from bench to clinic. Signal Transduct Target Ther 6:402, 2021","DOI":"10.1038\/s41392-021-00791-1"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Gu S, Liang J, Zhang J, Liu Z, Miao Y, Wei Y, Li S, Gu J, Cui Y, Xiao T, Li X, Yang C:Baricitinib Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice by Inhibiting TGF-\u03b21 Signaling Pathway. Molecules 28:2195, 2023","DOI":"10.3390\/molecules28052195"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Travis MA, Sheppard D:TGF-\u03b2 activation and function in immunity. Annu Rev Immunol 32:51-82, 2014","DOI":"10.1146\/annurev-immunol-032713-120257"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Laskin DL, Malaviya R, Laskin JD:Role of Macrophages in Acute Lung Injury and Chronic Fibrosis Induced by Pulmonary Toxicants. Toxicol Sci 168:287-301, 2019","DOI":"10.1093\/toxsci\/kfy309"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Jin J, Togo S, Kadoya K, Tulafu M, Namba Y, Iwai M, Watanabe J, Nagahama K, Okabe T, Hidayat M, Kodama Y, Kitamura H, Ogura T, Kitamura N, Ikeo K, Sasaki S, Tominaga S, Takahashi K:Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-\u03b21. Respir Res 20:119, 2019","DOI":"10.1186\/s12931-019-1093-z"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Wang F, Wang S, Zhang C, Tian X, Zhou Y, Xuan W, Matteson EL, Luo F, Tschumperlin D, Vassallo R:Noncanonical JAK1\/STAT3 interactions with TGF-\u03b2 modulate myofibroblast transdifferentiation and fibrosis. Am J Physiol Lung Cell Mol Physiol 323:698-714, 2022","DOI":"10.1152\/ajplung.00428.2021"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Shenderov K, Collins SL, Powell JD, Horton MR:Immune dysregulation as a driver of idiopathic pulmonary fibrosis. J Clin Invest 131:e143226, 2021","DOI":"10.1172\/JCI143226"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, Cheever AW, Wynn TA:Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 207:535-552, 2010","DOI":"10.1084\/jem.20092121"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Zhang M, Zhang S:T Cells in Fibrosis and Fibrotic Diseases. Front Immunol 11:1142, 2020","DOI":"10.3389\/fimmu.2020.01142"}],"container-title":["The Journal of Medical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jmi\/72\/3.4\/72_298\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T03:57:35Z","timestamp":1762574255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jmi\/72\/3.4\/72_298\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":50,"journal-issue":{"issue":"3.4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2152\/jmi.72.298","relation":{},"ISSN":["1343-1420","1349-6867"],"issn-type":[{"value":"1343-1420","type":"print"},{"value":"1349-6867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}